Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Populus tremuloides pollen, also known as aspen pollen extract, is a biologic allergenic extract derived from the pollen of the quaking aspen tree (Populus tremuloides). It is developed and manufactured by Greer Laboratories, Inc. and is indicated for both the diagnosis of and immunotherapy for allergic conditions such as allergic rhinitis caused by sensitivity to aspen pollen. For diagnosis, it is administered via percutaneous or intradermal routes to elicit a localized allergic reaction (wheal and flare) in sensitized individuals. As a therapeutic, it is administered subcutaneously in gradually increasing doses. This process, known as immunotherapy, works by desensitizing the patient's immune system to the pollen allergens, thereby reducing the severity of allergic symptoms upon natural exposure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Populus tremuloides pollen.